Rhonda Hill, APRN
Family · Spartanburg, SCNPI 1235432154
Payments from drug & device makers
Across 177 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$674
- Novo Nordisk$490
- AstraZeneca$390
- Lilly USA, LLC$241
- Otsuka America Pharmaceutical, Inc.$157
- GSK$128
- plus $907 from 22 others
What the payments were for
- Food & beverage$2,987100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $674 |
| Novo Nordisk | 31 | $490 |
| AstraZeneca | 15 | $390 |
| Lilly USA, LLC | 13 | $241 |
| Otsuka America Pharmaceutical, Inc. | 7 | $157 |
| GSK | 7 | $128 |
| Idorsia Pharmaceuticals US Inc | 6 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| Exact Sciences | 5 | $74 |
| Edwards Lifesciences | 2 | $59 |
| Inari Medical, Inc. | 2 | $58 |
| Alkermes, Inc. | 3 | $58 |
| Pfizer | 2 | $43 |
| Abbott | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Nevro Corp. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Astellas Pharma US Inc | 1 | $29 |
| Novartis | 2 | $27 |
| Mylan Specialty L.p. | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $18 |
| Amgen | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| United Therapeutics Corporation | 1 | $14 |
How this compares
$2,987 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $100,738 |
| TrulicityDulaglutide | 76 | $93,734 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $82,643 |
| RybelsusSemaglutide | 52 | $73,587 |
| JanuviaSitagliptin Phosphate | 37 | $37,820 |
| FarxigaDapagliflozin Propanediol | 43 | $34,479 |
| EliquisApixaban | 39 | $30,219 |
| VraylarCariprazine Hcl | 19 | $27,824 |
| MounjaroTirzepatide | 23 | $26,395 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $21,246 |
| UbrelvyUbrogepant | 18 | $19,405 |
| MyrbetriqMirabegron | 20 | $17,204 |
| LinzessLinaclotide | 23 | $15,070 |
| QuliptaAtogepant | 13 | $14,625 |
| XareltoRivaroxaban | 15 | $12,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $490 | $174,325142 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $241 | $120,12999 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $128 | $100,496106 claims |
| AbbVieVraylar, Ubrelvy, Linzess, Qulipta | $674 | $76,92373 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $390 | $51,16586 claims |
| PfizerEliquis | $43 | $30,21939 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $17,20420 claims |
| Johnson & JohnsonXarelto | $14 | $12,51615 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $104 | $5,30111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.
Other family in Spartanburg
- Ashley McKinneySpartanburg$16K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.